

Glenda Halliday

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7383115/publications.pdf>

Version: 2024-02-01

700
papers

72,038
citations

813

118
h-index

983

237
g-index

728
all docs

728
docs citations

728
times ranked

47213
citing authors

#	ARTICLE	IF	CITATIONS
1	Parkinsonism and cerebrovascular disease. Journal of the Neurological Sciences, 2022, 433, 120011.	0.6	11
2	Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of Î±-Synuclein Autoantibodies in Human Plasma. Bioconjugate Chemistry, 2022, , .	3.6	0
3	Limbic thalamus atrophy is associated with visual hallucinations in Lewy body disorders. Neurobiology of Aging, 2022, 112, 122-128.	3.1	3
4	Identifying gene expression profiles associated with neurogenesis and inflammation in the human subependymal zone from development through aging. Scientific Reports, 2022, 12, 40.	3.3	8
5	Cerebellar integrity and contributions to cognition in C9orf72-mediated frontotemporal dementia. Cortex, 2022, 149, 73-84.	2.4	2
6	Prion-like Î±-synuclein pathology in the brain of infants with Krabbe disease. Brain, 2022, 145, 1257-1263.	7.6	9
7	Narrow doorways alter brain connectivity and step patterns in isolated REM sleep behaviour disorder. NeuroImage: Clinical, 2022, 33, 102958.	2.7	3
8	Examining the presence and nature of delusions in Alzheimerâ€™s disease and frontotemporal dementia syndromes. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	4
9	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Brain, 2022, 145, 1598-1609.	7.6	17
10	Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia. Npj Parkinson's Disease, 2022, 8, 16.	5.3	4
11	Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. Science Advances, 2022, 8, eabm5386.	10.3	68
12	Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. Npj Parkinson's Disease, 2022, 8, 34.	5.3	18
13	Schizotypal traits across the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum: pathomechanistic insights. Journal of Neurology, 2022, , 1.	3.6	0
14	Thalamic and Cerebellar Regional Involvement across the ALSâ€“FTD Spectrum and the Effect of C9orf72. Brain Sciences, 2022, 12, 336.	2.3	6
15	Immune responses in the Parkinson's disease brain. Neurobiology of Disease, 2022, 168, 105700.	4.4	30
16	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2022, 37, 1131-1148.	3.9	222
17	Sex-specific lipid dysregulation in the <i>Abca7</i> knockout mouse brain. Brain Communications, 2022, 4, .	3.3	4
18	Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain, 2022, 145, 3108-3130.	7.6	25

#	ARTICLE	IF	CITATIONS
19	Overlap between Central and Peripheral Transcriptomes in Parkinson's Disease but Not Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 5200.	4.1	5
20	Lipid pathway dysfunction is prevalent in patients with Parkinson's disease. Brain, 2022, 145, 3472-3487.	7.6	25
21	A small molecule toll-like receptor antagonist rescues α -synuclein fibril pathology. Journal of Biological Chemistry, 2022, 298, 102260.	3.4	6
22	Utility of the Addenbrooke's Cognitive Examination III online calculator to differentiate the primary progressive aphasia variants. Brain Communications, 2022, 4, .	3.3	6
23	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 86-95.	1.9	174
24	Evaluating a novel behavioral paradigm for visual hallucinations in Dementia with Lewy bodies. Aging Brain, 2021, 1, 100011.	1.3	2
25	Clinical and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-Variant Frontotemporal Dementia and Alzheimer Disease. Neurology, 2021, 96, e1743-e1754.	1.1	24
26	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
27	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	8.8	49
28	Globular glial tauopathy with a mutation in MAPT and unusual TDP-43 proteinopathy in a patient with behavioural-variant frontotemporal dementia. Acta Neuropathologica, 2021, 141, 791-794.	7.7	4
29	Defining early changes in Alzheimer's disease from RNA sequencing of brain regions differentially affected by pathology. Scientific Reports, 2021, 11, 4865.	3.3	23
30	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. Journal of Parkinson's Disease, 2021, 11, 395-404.	2.8	56
31	Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2021, 47, 979-989.	3.2	31
32	Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. Movement Disorders, 2021, 36, 2085-2093.	3.9	23
33	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
34	Prodromal neuroinvasion of pathological α -synuclein in brainstem reticular nuclei and white matter lesions in a model of α -synucleinopathy. Brain Communications, 2021, 3, fcb104.	3.3	7
35	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 2192-2199.	3.3	6
36	Anterior-posterior electrophysiological activity characterizes Parkinsonian visual misperceptions. Neurology and Clinical Neuroscience, 2021, 9, 312-318.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Reduced adult neurogenesis is associated with increased macrophages in the subependymal zone in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 6880-6895.	7.9	20
38	Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALS-FTD spectrum. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1576-1591.	3.7	11
39	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1761-1772.	2.8	15
40	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 65.	5.3	74
41	PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612476.	3.7	32
42	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	30.5	391
43	Native Separation and Metallation Analysis of SOD1 Protein from the Human Central Nervous System: a Methodological Workflow. <i>Analytical Chemistry</i> , 2021, 93, 11108-11115.	6.5	6
44	Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. <i>Journal of Neuroinflammation</i> , 2021, 18, 177.	7.2	18
45	Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson's Disease Patient Monocytes and Inversely Correlates with Motor Severity. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1157-1165.	2.8	11
46	Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months. <i>Neurology</i> , 2021, 97, e1031-e1040.	1.1	11
47	Early white matter pathology in the fornix of the limbic system in Huntington disease. <i>Acta Neuropathologica</i> , 2021, 142, 791-806.	7.7	13
48	Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. <i>Neurobiology of Disease</i> , 2021, 157, 105426.	4.4	7
49	Glycoprotein Pathways Altered in Frontotemporal Dementia With Autoimmune Disease. <i>Frontiers in Immunology</i> , 2021, 12, 736260.	4.8	2
50	Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2021, 107, 11-20.	3.1	1
51	Hypothalamic symptoms of frontotemporal dementia disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 269-280.	1.8	9
52	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. <i>Acta Neuropathologica</i> , 2021, 141, 159-172.	7.7	107
53	The aging brain and brain banking. , 2021, , 103-112.		0
54	Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1153-1161.	2.6	11

#	ARTICLE	IF	CITATIONS
55	Tackling clinical heterogeneity across the amyotrophic lateral sclerosis“frontotemporal dementia spectrum using a transdiagnostic approach. Brain Communications, 2021, 3, fca257.	3.3	16
56	Increased VLCFA-lipids and ELOVL4 underlie neurodegeneration in frontotemporal dementia. Scientific Reports, 2021, 11, 21348.	3.3	11
57	Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage. Frontiers in Neurology, 2021, 12, 743688.	2.4	6
58	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. Communications Medicine, 2021, 1, .	4.2	14
59	Presence of co“pathology in sporadic early“onset Alzheimer disease versus dominantly inherited Alzheimer disease. Alzheimer's and Dementia, 2021, 17, e055045.	0.8	0
60	Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. Brain, 2020, 143, 31-46.	7.6	53
61	Intracellular and secreted forms of clusterin are elevated early in Alzheimer's disease and associate with both A“2 and tau pathology. Neurobiology of Aging, 2020, 89, 129-131.	3.1	19
62	Evaluating the Sustained Attention Response Task to Quantify Cognitive Fluctuations in Dementia With Lewy Bodies. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 333-339.	2.3	7
63	Assessing the role of nocturnal core body temperature dysregulation as a biomarker of neurodegeneration. Journal of Sleep Research, 2020, 29, e12939.	3.2	19
64	Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. Journal of Neurology, 2020, 267, 380-389.	3.6	17
65	Are mutations in <i>MAPT</i> associated with GGT type III?. Neuropathology and Applied Neurobiology, 2020, 46, 406-409.	3.2	4
66	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
67	LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Neurobiology of Disease, 2020, 144, 105049.	4.4	10
68	The complex relationship between genotype, pathology and phenotype in familial dementia. Neurobiology of Disease, 2020, 145, 105082.	4.4	6
69	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	3.7	38
70	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
71	Author response: The underacknowledged PPA-ALS: A unique clinicopathologic subtype with strong heritability. Neurology, 2020, 94, 283-283.	1.1	0
72	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Scientific Reports, 2020, 10, 13741.	3.3	26

#	ARTICLE	IF	CITATIONS
73	A Practical Approach to Differentiate the Frontotemporal Tauopathy Subtypes. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1122-1126.	1.7	1
74	Circular RNAs: The Brain Transcriptome Comes Full Circle. Trends in Neurosciences, 2020, 43, 752-766.	8.6	51
75	Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12060.	3.7	12
76	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	1.5	31
77	Alzheimer's amyloid β and tau protein accumulation is associated with decreased expression of the LDL receptor-associated protein in human brain tissue. Brain and Behavior, 2020, 10, e01672.	2.2	6
78	Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. Acta Neuropathologica Communications, 2020, 8, 76.	5.2	20
79	The Neural Signature of Impaired <scp>Dual-tasking</scp> in Idiopathic Rapid Eye Movement Sleep Behavior Disorder Patients. Movement Disorders, 2020, 35, 1596-1606.	3.9	12
80	CYLD is a causative gene for frontotemporal dementia " amyotrophic lateral sclerosis. Brain, 2020, 143, 783-799.	7.6	62
81	Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease. Nature Communications, 2020, 11, 1238.	12.8	85
82	Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 162-171.	1.9	8
83	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 22.	6.2	74
84	Accelerated loss of hypoxia response in zebrafish with familial Alzheimer's disease-like mutation of presenilin 1. Human Molecular Genetics, 2020, 29, 2379-2394.	2.9	12
85	Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. Scientific Reports, 2020, 10, 3640.	3.3	39
86	Invited Reply to: "Instrumental Analysis of Gait Abnormalities in Idiopathic Rapid Eye Movement Sleep Behavior Disorder" Movement Disorders, 2020, 35, 195-196.	3.9	0
87	Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. Npj Parkinson's Disease, 2020, 6, 2.	5.3	32
88	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15
89	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	5.2	27
90	ESHRD: deconvolution of brain homogenate RNA expression data to identify cell-type-specific alterations in Alzheimer's disease. Aging, 2020, 12, 4124-4162.	3.1	4

#	ARTICLE	IF	CITATIONS
91	Neglected cytotoxic T cell invasion of the brain: how specific for Parkinson's disease?. <i>Brain</i> , 2020, 143, 3518-3521.	7.6	3
92	Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes. <i>Bio-protocol</i> , 2020, 10, e3572.	0.4	2
93	<i>SIRT1</i> is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 361-379.	3.2	31
94	Alpha-synuclein: prion or prion-like?. <i>Acta Neuropathologica</i> , 2019, 138, 509-514.	7.7	14
95	CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. <i>Journal of Biological Chemistry</i> , 2019, 294, 14149-14162.	3.4	10
96	Reply: LATE to the PART-y. <i>Brain</i> , 2019, 142, e48-e48.	7.6	11
97	Autophagy activation promotes clearance of α -synuclein inclusions in fibril-seeded human neural cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 14241-14256.	3.4	76
98	Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α -synuclein chaperone. <i>Brain</i> , 2019, 142, 2845-2859.	7.6	44
99	Neuroinflammation in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2019, 15, 540-555.	10.1	159
100	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3161.	4.1	173
101	Parkinson's progression prediction using machine learning and serum cytokines. <i>Npj Parkinson's Disease</i> , 2019, 5, 14.	5.3	63
102	Cross-examining candidate genes implicated in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2019, 7, 117.	5.2	22
103	Chronic traumatic encephalopathy in two former Australian National Rugby League players. <i>Acta Neuropathologica Communications</i> , 2019, 7, 97.	5.2	28
104	Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease. <i>Neurobiology of Disease</i> , 2019, 130, 104524.	4.4	20
105	TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. <i>Neurology</i> , 2019, 93, e1748-e1755.	1.1	20
106	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	10.2	1,414
107	Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. <i>Genome Medicine</i> , 2019, 11, 54.	8.2	191
108	Letter to the Editor. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 975-977.	1.7	3

#	ARTICLE	IF	CITATIONS
109	Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA* ^{A53T}) mouse lines. <i>Acta Neuropathologica</i> , 2019, 137, 437-454.	7.7	58
110	Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 486-495.	3.7	40
111	Cellular and regional vulnerability in frontotemporal tauopathies. <i>Acta Neuropathologica</i> , 2019, 138, 705-727.	7.7	49
112	Subtle gait and balance impairments occur in idiopathic rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2019, 34, 1374-1380.	3.9	36
113	Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 605-614.	1.7	19
114	Targeted, High-Resolution RNA Sequencing of Non-coding Genomic Regions Associated With Neuropsychiatric Functions. <i>Frontiers in Genetics</i> , 2019, 10, 309.	2.3	28
115	Von Economo Neurons in Behavioral Variant Frontotemporal Dementia with Underlying Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 963-967.	2.6	10
116	Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. <i>Neurology</i> , 2019, 92, e2472-e2482.	1.1	16
117	Temporal evolution of microglia and α -synuclein accumulation following foetal grafting in Parkinson's disease. <i>Brain</i> , 2019, 142, 1690-1700.	7.6	75
118	α^2 and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	96
119	Impaired Color Discrimination—A Specific Marker of Hallucinations in Lewy Body Disorders. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 257-264.	2.3	11
120	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	7.6	873
121	Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease. <i>Brain Pathology</i> , 2019, 29, 813-825.	4.1	24
122	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
123	Dopamine depletion alters macroscopic network dynamics in Parkinson's disease. <i>Brain</i> , 2019, 142, 1024-1034.	7.6	50
124	The <i>C9orf72</i> hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 310-316.	1.7	16
125	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	4.4	29
126	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	7.7	90

#	ARTICLE	IF	CITATIONS
127	The underacknowledged PPA-ALS. <i>Neurology</i> , 2019, 92, e1354-e1366.	1.1	29
128	Heritability in frontotemporal tauopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 115-124.	2.4	17
129	060â€...Impaired color discrimination is associated with hallucinations in dementia with lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A19.3-A20.	1.9	0
130	001â€...Altered interval timing as a novel marker of cognitive fluctuations in lewy body dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A1.1-A1.	1.9	2
131	037â€...Frontotemporal dementia or frontal variant alzheimerâ€™s disease? A case series. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A13.1-A13.	1.9	0
132	093â€...How to diagnose lewy body dementia? Prevalence and underlying relationship between clinical and neuropsychological features of DLB. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A30.1-A30.	1.9	0
133	095â€...Predicting parkinsonâ€™s and dementia with lewy bodies (pre-D) research study â€“ a sydney-based longitudinal biobanking program. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A30.3-A31.	1.9	0
134	Reductions in COQ2 Expression Relate to Reduced ATP Levels in Multiple System Atrophy Brain. <i>Frontiers in Neuroscience</i> , 2019, 13, 1187.	2.8	11
135	Structural heterogeneity of Î±-synuclein fibrils amplified from patient brain extracts. <i>Nature Communications</i> , 2019, 10, 5535.	12.8	153
136	Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimerâ€™s disease and not in other tauopathies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 195.	5.2	18
137	LRRK2â€-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. <i>Movement Disorders</i> , 2019, 34, 406-415.	3.9	83
138	Predictors of survival and progression in behavioural variant frontotemporal dementia. <i>European Journal of Neurology</i> , 2019, 26, 774-779.	3.3	22
139	Apolipoprotein D Upregulation in Alzheimerâ€™s Disease but Not Frontotemporal Dementia. <i>Journal of Molecular Neuroscience</i> , 2019, 67, 125-132.	2.3	29
140	Brain Banking for Research into Neurodegenerative Disorders and Ageing. <i>Neuroscience Bulletin</i> , 2019, 35, 283-288.	2.9	14
141	Gutâ€“brain axis and the spread of Î±-synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.	3.9	144
142	Molecular Pathogenesis of the Tauopathies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 239-261.	22.4	161
143	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	3.1	13
144	Region- and Cell-specific Aneuploidy in Brain Aging and Neurodegeneration. <i>Neuroscience</i> , 2018, 374, 326-334.	2.3	28

#	ARTICLE	IF	CITATIONS
145	Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. <i>Brain</i> , 2018, 141, 486-495.	7.6	36
146	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. <i>Brain</i> , 2018, 141, 521-534.	7.6	114
147	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	10.2	97
148	Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. <i>EMBO Reports</i> , 2018, 19, .	4.5	88
149	Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. <i>American Journal of Pathology</i> , 2018, 188, 1447-1456.	3.8	8
150	Physiological changes in neurodegeneration – mechanistic insights and clinical utility. <i>Nature Reviews Neurology</i> , 2018, 14, 259-271.	10.1	72
151	Accumulation of dysfunctional SOD1 protein in Parkinson’s disease is not associated with mutations in the SOD1 gene. <i>Acta Neuropathologica</i> , 2018, 135, 155-156.	7.7	23
152	MSA prions exhibit remarkable stability and resistance to inactivation. <i>Acta Neuropathologica</i> , 2018, 135, 49-63.	7.7	70
153	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.1	23
154	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	10.2	195
155	Multiple neuronal pathologies are common in young patients with pathologically proven Frontotemporal lobar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 522-532.	3.2	9
156	P1405: VISUAL ASSESSMENT OF 123I-AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. <i>Alzheimer's and Dementia</i> , 2018, 14, P459.	0.8	0
157	A52...SIRT1 is increased in affected brain regions in huntington disease impacting hypothalamic metabolic pathways. , 2018, , .		0
158	O13...Lipid metabolism and body composition in frontotemporal dementia-amyotrophic lateral sclerosis spectrum: effect on survival and disease progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A6.3-A7.	1.9	0
159	Altered High Density Lipoprotein Composition in Behavioral Variant Frontotemporal Dementia. <i>Frontiers in Neuroscience</i> , 2018, 12, 847.	2.8	16
160	110...Atrophy of the mediodorsal thalamus is associated with visual hallucinations in lewy body diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A43.3-A44.	1.9	0
161	Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. <i>ENeuro</i> , 2018, 5, ENEURO.0234-18.2018.	1.9	10
162	LRP10 in 1-synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032-1033.	10.2	11

#	ARTICLE	IF	CITATIONS
163	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	7.6	39
164	Psychiatric disorders in C9orf72 kindreds. <i>Neurology</i> , 2018, 91, e1498-e1507.	1.1	75
165	Intrafamilial Phenotypic Variability in the C9orf72 Gene Expansion: 2 Case Studies. <i>Frontiers in Psychology</i> , 2018, 9, 1615.	2.1	9
166	Reply: Will FTLD-tau work for all when FTDP-17 retires?. <i>Brain</i> , 2018, 141, e63-e63.	7.6	3
167	Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 15446.	3.3	82
168	Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2018, 58, 70-74.	1.5	19
169	Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. <i>Neurobiology of Disease</i> , 2018, 120, 76-87.	4.4	16
170	Lipidomics Analysis of Behavioral Variant Frontotemporal Dementia: A Scope for Biomarker Development. <i>Frontiers in Neurology</i> , 2018, 9, 104.	2.4	36
171	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	3.9	114
172	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	3.9	171
173	Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain. <i>Translational Psychiatry</i> , 2017, 7, e1003-e1003.	4.8	56
174	Selective neuronal vulnerability in Parkinson disease. <i>Nature Reviews Neuroscience</i> , 2017, 18, 101-113.	10.2	711
175	ALS/FTLD: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 177-196.	7.7	78
176	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 126-138.	6.1	23
177	Accelerated aging exacerbates a pre-existing pathology in a tau transgenic mouse model. <i>Aging Cell</i> , 2017, 16, 377-386.	6.7	29
178	Predicting Development of Amyotrophic Lateral Sclerosis in Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 163-170.	2.6	17
179	von Economo Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal Dementia Cases with and without a C9ORF72 Repeat Expansion. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 701-709.	2.6	30
180	The midbrain-to-pons ratio distinguishes progressive supranuclear palsy from non-fluent primary progressive aphasia. <i>European Journal of Neurology</i> , 2017, 24, 956-965.	3.3	11

#	ARTICLE	IF	CITATIONS
181	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a <scp>Parkinson disease patient. <i>Annals of Neurology</i> , 2017, 81, 46-57.	5.3	72
182	Authors' response to a reply to "A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients". <i>British Journal of Dermatology</i> , 2017, 176, 552-553.	1.5	2
183	LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. <i>Movement Disorders</i> , 2017, 32, 423-432.	3.9	39
184	Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain. <i>Acta Neuropathologica</i> , 2017, 134, 113-127.	7.7	78
185	Early-life decline in neurogenesis markers and age-related changes of TrkB splice variant expression in the human subependymal zone. <i>European Journal of Neuroscience</i> , 2017, 46, 1768-1778.	2.6	7
186	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,805
187	Multisite Assessment of Aging-Related Tau Astroglialopathy (ARTAG). <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 605-619.	1.7	38
188	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17013.	30.5	3,048
189	The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion. <i>NeuroImage: Clinical</i> , 2017, 13, 439-445.	2.7	60
190	Parkinson's Disease Is Not Simply a Prion Disorder. <i>Journal of Neuroscience</i> , 2017, 37, 9799-9807.	3.6	144
191	Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain. <i>Metallomics</i> , 2017, 9, 1447-1455.	2.4	89
192	Pathology and hippocampal atrophy in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2017, 16, 862-864.	10.2	87
193	The hummingbird identifies psp among patients with non-fluent primary progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, e1.19-e1.	1.9	0
194	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	3.9	608
195	Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 10-20.	2.4	38
196	Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. <i>Experimental Neurology</i> , 2017, 298, 202-209.	4.1	73
197	Exploring the Phenotype in Mild Cognitive Impairment to Aid the Prediction of Those at Risk of Transitioning to Parkinson Disease and Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017, 30, 196-205.	2.3	8
198	Clinical Aspects of Alzheimer's Disease. <i>Advances in Neurobiology</i> , 2017, 15, 31-53.	1.8	10

#	ARTICLE	IF	CITATIONS
199	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	3.1	12
200	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. <i>Neurobiology of Disease</i> , 2017, 97, 179-188.	4.4	40
201	Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. <i>Acta Neuropathologica</i> , 2017, 133, 303-319.	7.7	200
202	Increased aneuploidy is not a universal feature across α -synucleinopathies. <i>Movement Disorders</i> , 2017, 32, 475-476.	3.9	5
203	Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 773-783.	2.6	47
204	[S3a01a01]: MIXED PATHOLOGY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P877.	0.8	0
205	White matter changes in frontotemporal dementia and the C9ORF72 gene expansions. <i>Journal of the Neurological Sciences</i> , 2017, 381, 803.	0.6	0
206	Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 705-715.	2.6	20
207	Deletion of Alzheimer's Disease Risk Gene ABCA7 Alters White Adipose Tissue Development and Leptin Levels. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 237-247.	2.2	4
208	α -Synuclein Regulates Neuronal Cholesterol Efflux. <i>Molecules</i> , 2017, 22, 1769.	3.8	29
209	Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2017, 5, 76.	5.2	27
210	Decline in Proliferation and Immature Neuron Markers in the Human Subependymal Zone during Aging: Relationship to EGF- and FGF-Related Transcripts. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 274.	3.4	41
211	ROCK1 Is Associated with Alzheimer's Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic $A\beta$ Clearance. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 253.	3.7	23
212	Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0157924.	2.5	68
213	Mannose 6-Phosphate Receptor Is Reduced in α -Synuclein Overexpressing Models of Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0160501.	2.5	19
214	Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. <i>Movement Disorders</i> , 2016, 31, 889-897.	3.9	76
215	A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. <i>British Journal of Dermatology</i> , 2016, 175, 1073-1075.	1.5	88
216	Neuropathology of α -synuclein propagation and Braak hypothesis. <i>Movement Disorders</i> , 2016, 31, 152-160.	3.9	111

#	ARTICLE	IF	CITATIONS
217	Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with <scp>ATXN</scp>2 intermediate repeat expansions. <i>Annals of Neurology</i> , 2016, 79, 295-305.	5.3	29
218	Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2016, 175, 1363-1365.	1.5	16
219	Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. <i>Scientific Reports</i> , 2016, 6, 31391.	3.3	32
220	Neuronal network disintegration: common pathways linking neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1234-1241.	1.9	106
221	ABCA7 Mediates Phagocytic Clearance of Amyloid- β^2 in the Brain. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 569-584.	2.6	69
222	MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 26697.	3.3	84
223	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.	0.8	93
224	TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. <i>Journal of the Neurological Sciences</i> , 2016, 366, 197-201.	0.6	10
225	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	10.2	82
226	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. <i>Molecular Neurodegeneration</i> , 2016, 11, 61.	10.8	39
227	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	3.9	43
228	Characterization of circular <scp>RNA</scp>s landscape in multiple system atrophy brain. <i>Journal of Neurochemistry</i> , 2016, 139, 485-496.	3.9	79
229	Motor cortical function determines prognosis in sporadic ALS. <i>Neurology</i> , 2016, 87, 513-520.	1.1	76
230	Expanding the phenotypic associations of globular glial tau subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 6-13.	2.4	23
231	Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. <i>Journal of Neurology</i> , 2016, 263, 1593-1603.	3.6	48
232	Animal modeling an oligodendroglialopathy " multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 12.	5.2	16
233	Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. <i>Lancet Neurology</i> , The, 2016, 15, 332-342.	10.2	120
234	Cerebellar atrophy in Parkinson's disease and its implication for network connectivity. <i>Brain</i> , 2016, 139, 845-855.	7.6	103

#	ARTICLE	IF	CITATIONS
235	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	3.1	78
236	Aging-related tau astroglialopathy (ARTAG): harmonized evaluation strategy. <i>Acta Neuropathologica</i> , 2016, 131, 87-102.	7.7	380
237	The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. <i>Journal of Chemical Neuroanatomy</i> , 2016, 76, 98-107.	2.1	54
238	Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 24, 89-94.	2.2	28
239	Distinctive pathological mechanisms involved in primary progressive Aphasias. <i>Neurobiology of Aging</i> , 2016, 38, 82-92.	3.1	45
240	Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. <i>Neurobiology of Learning and Memory</i> , 2016, 130, 34-43.	1.9	24
241	The frontotemporal dementia-motor neuron disease continuum. <i>Lancet, The</i> , 2016, 388, 919-931.	13.7	294
242	Strand-specific RNA-sequencing analysis of multiple system atrophy brain transcriptome. <i>Neuroscience</i> , 2016, 322, 234-250.	2.3	24
243	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	3.9	1,033
244	Neuropathologic assessment of participants in two multicenter longitudinal observational studies: The Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). <i>Neuropathology</i> , 2015, 35, 390-400.	1.2	68
245	The relationships between mild cognitive impairment and phenotype in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2015, 1, 15015.	5.3	20
246	Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson's disease: a task-based fMRI study. <i>Npj Parkinson's Disease</i> , 2015, 1, 15003.	5.3	75
247	Fatty Acid Composition of the Anterior Cingulate Cortex Indicates a High Susceptibility to Lipid Peroxidation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 175-185.	2.8	16
248	Early in vivo Effects of the Human Mutant Amyloid- β Protein Precursor (hA β PPSwInd) on the Mouse Olfactory Bulb. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 443-457.	2.6	5
249	Validation of the Psychosis and Hallucinations Questionnaire in Non-demented Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 175-181.	1.5	28
250	Restricted disease propagation in multiple system atrophy with prolonged survival. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 681-685.	3.2	4
251	Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 843-848.	3.2	31
252	Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1639-1647.	3.9	123

#	ARTICLE	IF	CITATIONS
253	Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. <i>Movement Disorders</i> , 2015, 30, 796-804.	3.9	32
254	Terra incognita—cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 121.	3.4	23
255	SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	16
256	Aneuploidy in Lewy body diseases. <i>Neurobiology of Aging</i> , 2015, 36, 1253-1260.	3.1	23
257	Progressive supranuclear palsy finally has a clinically measureable α abnormality. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 241-241.	1.9	0
258	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	3.9	4,389
259	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
260	Unusual α -synuclein and cerebellar pathologies in a case of hereditary myoclonus-dystonia without <i>SCG10</i> mutation. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 837-842.	3.2	1
261	PART is part of Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 749-756.	7.7	256
262	TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. <i>Brain</i> , 2015, 138, 3110-3122.	7.6	94
263	Re-evaluating the glio-centric view of multiple system atrophy by highlighting the neuronal involvement: Figure 1. <i>Brain</i> , 2015, 138, 2116-2119.	7.6	21
264	Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy. <i>Neurogenetics</i> , 2015, 16, 107-122.	1.4	33
265	Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. <i>Neurogenetics</i> , 2015, 16, 201-213.	1.4	18
266	High expression of long intervening non-coding RNA OLMALINC in the human cortical white matter is associated with regulation of oligodendrocyte maturation. <i>Molecular Brain</i> , 2015, 8, 2.	2.6	25
267	Early-onset axonal pathology in a novel <i>PS1</i> <i>S28</i> transgenic mouse model of frontotemporal lobar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 906-925.	3.2	41
268	FTD and ALS—translating mouse studies into clinical trials. <i>Nature Reviews Neurology</i> , 2015, 11, 360-366.	10.1	64
269	Generation and characterization of novel conformation-specific monoclonal antibodies for α -synuclein pathology. <i>Neurobiology of Disease</i> , 2015, 79, 81-99.	4.4	116
270	Protective properties of lysozyme on β -amyloid pathology: implications for Alzheimer disease. <i>Neurobiology of Disease</i> , 2015, 83, 122-133.	4.4	58

#	ARTICLE	IF	CITATIONS
271	Progression in Behavioral Variant Frontotemporal Dementia. JAMA Neurology, 2015, 72, 1501.	9.0	47
272	Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathologica Communications, 2015, 3, 47.	5.2	69
273	The differentiation of progressive supranuclear palsy. Neurodegenerative Disease Management, 2015, 5, 385-388.	2.2	2
274	Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). Neurobiology of Disease, 2015, 82, 445-454.	4.4	33
275	Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathologica, 2015, 130, 661-678.	7.7	61
276	Evidence for α -synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5308-17.	7.1	578
277	IsCHCHD10Pro34Ser pathogenic for frontotemporal dementia and amyotrophic lateral sclerosis?: Figure 1. Brain, 2015, 138, e385-e385.	7.6	16
278	Eating behavior in frontotemporal dementia. Neurology, 2015, 85, 1310-1317.	1.1	72
279	$\text{A}\beta$ -dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease. Nature Communications, 2015, 6, 8836.	12.8	70
280	The role of transcriptional control in multiple system atrophy. Neurobiology of Aging, 2015, 36, 394-400.	3.1	10
281	Reply: Lysosomal dysfunction in Parkinson's disease. Brain, 2015, 138, e340-e340.	7.6	1
282	Inflammation is genetically implicated in Parkinson's disease. Neuroscience, 2015, 302, 89-102.	2.3	182
283	Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer's disease. Current Alzheimer Research, 2015, 12, 745-751.	1.4	9
284	Influence of Single Nucleotide Polymorphisms in COMT , MAO-A , and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease. Neurodegenerative Diseases, 2014, 13, 24-28.	1.4	56
285	Increased Ndfip1 in the Substantia Nigra of Parkinsonian Brains Is Associated with Elevated Iron Levels. PLoS ONE, 2014, 9, e87119.	2.5	28
286	Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. PLoS ONE, 2014, 9, e105632.	2.5	79
287	Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Frontiers in Molecular Neuroscience, 2014, 7, 57.	2.9	73
288	Analysis of Tyrosine Hydroxylase Isoforms and Phosphorylation in Parkinson's Disease. , 2014, , 15.		0

#	ARTICLE	IF	CITATIONS
289	Exploring Myelin Dysfunction in Multiple System Atrophy. <i>Experimental Neurobiology</i> , 2014, 23, 337-344.	1.6	33
290	ABCA5 Regulates Amyloid- β Peptide Production and is Associated with Alzheimer's Disease Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 857-869.	2.6	40
291	Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 150.	5.2	62
292	Alpha-synuclein biology in Lewy body diseases. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 73.	6.2	288
293	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	2.9	178
294	H04 Gene Expression Changes In Emotion And Metabolism Regulating Neuropeptide Systems In The Hypothalamus In Clinical Huntington Disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A53-A53.	1.9	0
295	DNA methylation of the <i>MAPT</i> gene in Parkinson's disease cohorts and modulation by vitamin E <i>In Vitro</i> . <i>Movement Disorders</i> , 2014, 29, 1606-1614.	3.9	79
296	Visual hallucinations in Parkinson's disease: Theoretical models. <i>Movement Disorders</i> , 2014, 29, 1591-1598.	3.9	70
297	The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 2206-2219.	3.6	111
298	Systemic metabolism in frontotemporal dementia. <i>Neurology</i> , 2014, 83, 1812-1818.	1.1	48
299	Prodegenerative α -syn expression in oligodendroglial α -synuclein models of multiple system atrophy. <i>Neurobiology of Disease</i> , 2014, 63, 171-183.	4.4	10
300	c-Abl phosphorylates α -synuclein and regulates its degradation: implication for α -synuclein clearance and contribution to the pathogenesis of Parkinson's disease. <i>Human Molecular Genetics</i> , 2014, 23, 2858-2879.	2.9	176
301	Lipid dysfunction and pathogenesis of multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 15.	5.2	40
302	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. <i>Acta Neuropathologica</i> , 2014, 127, 407-418.	7.7	123
303	The neurobiological basis of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 634-650.	3.9	282
304	Beyond the temporal pole: limbic memory circuit in the semantic variant of primary progressive aphasia. <i>Brain</i> , 2014, 137, 2065-2076.	7.6	50
305	α -Synucleinopathy phenotypes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S62-S67.	2.2	272
306	Reduced glucocerebrosidase is associated with increased α -synuclein in sporadic Parkinson's disease. <i>Brain</i> , 2014, 137, 834-848.	7.6	397

#	ARTICLE	IF	CITATIONS
307	Copper pathology in vulnerable brain regions in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 858-866.	3.1	188
308	Longitudinal white matter changes in frontotemporal dementia subtypes. <i>Human Brain Mapping</i> , 2014, 35, 3547-3557.	3.6	77
309	Glucocerebrosidase deficits in sporadic Parkinson disease. <i>Autophagy</i> , 2014, 10, 1350-1351.	9.1	49
310	New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 865-870.	1.9	195
311	Misfolded proteins in Huntington disease fetal grafts: Further evidence of cell-to-cell transfer?. <i>Annals of Neurology</i> , 2014, 76, 20-21.	5.3	2
312	Heritability in frontotemporal dementia: more missing pieces?. <i>Journal of Neurology</i> , 2014, 261, 2170-2177.	3.6	27
313	Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. <i>Brain</i> , 2014, 137, 2493-2508.	7.6	232
314	Biomarkers in dementia: clinical utility and new directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1426-1434.	1.9	119
315	Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 518-526.	3.9	112
316	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	10.2	302
317	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	3.9	379
318	Tricks of the mind: Visual hallucinations as disorders of attention. <i>Progress in Neurobiology</i> , 2014, 116, 58-65.	5.7	156
319	Distribution of Pathology in Frontal Variant Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 63-70.	2.6	53
320	P1-039: MAPT METHYLATION IN ALZHEIMER'S DISEASE. , 2014, 10, P317-P318.		3
321	DAT-SPECT diagnoses dopamine depletion, but not PD. <i>Movement Disorders</i> , 2014, 29, 1705-1706.	3.9	16
322	Alpha Synuclein in Parkinson's Disease. , 2014, , 691-726.		4
323	The Role of Astrocytes in Parkinson's Disease. , 2014, , 127-144.		3
324	Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms. <i>PLoS ONE</i> , 2014, 9, e102909.	2.5	74

#	ARTICLE	IF	CITATIONS
325	Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. <i>Movement Disorders</i> , 2013, 28, 1351-1359.	3.9	20
326	Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. <i>Acta Neuropathologica Communications</i> , 2013, 1, 33.	5.2	48
327	The pathogenesis of cingulate atrophy in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013, 1, 30.	5.2	17
328	ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2013, 1, 11.	5.2	61
329	Pathway Analysis of the Human Brain Transcriptome in Disease. <i>Journal of Molecular Neuroscience</i> , 2013, 51, 28-36.	2.3	17
330	Can we clinically diagnose dementia with Lewy bodies yet?. <i>Translational Neurodegeneration</i> , 2013, 2, 4.	8.0	43
331	Frontotemporal dementia's amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. <i>Acta Neuropathologica</i> , 2013, 125, 523-533.	7.7	24
332	Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. <i>Brain</i> , 2013, 136, 2419-2431.	7.6	965
333	Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. <i>Movement Disorders</i> , 2013, 28, 1804-1806.	3.9	2
334	Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. <i>Neurobiology of Aging</i> , 2013, 34, 873-886.	3.1	44
335	Motor deficits associated with changes in A β -amyloid in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 475-476.	1.9	1
336	An Improved High-Throughput Lipid Extraction Method for the Analysis of Human Brain Lipids. <i>Lipids</i> , 2013, 48, 307-318.	1.7	76
337	DNA extraction from fresh-frozen and formalin-fixed, paraffin-embedded human brain tissue. <i>Neuroscience Bulletin</i> , 2013, 29, 649-654.	2.9	25
338	Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. <i>Neurobiology of Aging</i> , 2013, 34, 2235.e11-2235.e13.	3.1	13
339	LRRK2 interactions with α -synuclein in Parkinson's disease brains and in cell models. <i>Journal of Molecular Medicine</i> , 2013, 91, 513-522.	3.9	68
340	Unlocking the secrets of LRRK2 function with selective kinase inhibitors. <i>Future Neurology</i> , 2013, 8, 347-357.	0.5	4
341	Localization of copper and copper transporters in the human brain. <i>Metallomics</i> , 2013, 5, 43-51.	2.4	121
342	ABCA8 stimulates sphingomyelin production in oligodendrocytes. <i>Biochemical Journal</i> , 2013, 452, 401-410.	3.7	40

#	ARTICLE	IF	CITATIONS
343	Endogenous progesterone levels and frontotemporal dementia: modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model. DMM Disease Models and Mechanisms, 2013, 6, 1198-204.	2.4	10
344	Retrosplenial Cortex (BA 29) Volumes in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2013, 35, 177-182.	1.5	24
345	Tenuigenin Attenuates α -Synuclein-Induced Cytotoxicity by Down-Regulating Polo-Like Kinase 3. CNS Neuroscience and Therapeutics, 2013, 19, 688-694.	3.9	15
346	Increased Expression of ABCA8 in Multiple System Atrophy Brain is Associated with Changes in Pathogenic Proteins. Journal of Parkinson's Disease, 2013, 3, 331-339.	2.8	19
347	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	9.0	374
348	Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients. Journal of Parkinson's Disease, 2013, 3, 145-152.	2.8	44
349	FAS-Dependent Cell Death in α -Synuclein Transgenic Oligodendrocyte Models of Multiple System Atrophy. PLoS ONE, 2013, 8, e55243.	2.5	28
350	Elevation in Sphingomyelin Synthase Activity Is Associated with Increases in Amyloid-Beta Peptide Generation. PLoS ONE, 2013, 8, e74016.	2.5	17
351	Unique Transcriptome Patterns of the White and Grey Matter Corroborate Structural and Functional Heterogeneity in the Human Frontal Lobe. PLoS ONE, 2013, 8, e78480.	2.5	40
352	<i>C9ORF72</i> repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology, 2012, 79, 995-1001.	1.1	108
353	In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease. Brain, 2012, 135, 3015-3025.	7.6	157
354	Is Seladin-1 Really a Selective Alzheimer's Disease Indicator?. Journal of Alzheimer's Disease, 2012, 30, 35-39.	2.6	22
355	Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans. British Journal of Dermatology, 2012, 167, 631-636.	1.5	25
356	Srp20 regulates TrkB pre-mRNA splicing to generate TrkB ^{Shc} transcripts with implications for Alzheimer's disease. Journal of Neurochemistry, 2012, 123, 159-171.	3.9	28
357	An evidence base for noradrenergic deficits in Parkinson's disease. Movement Disorders, 2012, 27, 1589-1591.	3.9	7
358	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathologica, 2012, 124, 373-382.	7.7	89
359	Changes in Sphingomyelin Level Affect Alpha-Synuclein and ABCA5 Expression. Journal of Parkinson's Disease, 2012, 2, 41-46.	2.8	29
360	Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. Neuroscience, 2012, 210, 363-374.	2.3	33

#	ARTICLE	IF	CITATIONS
361	Role of hippocampin in mediating A β toxicity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1247-1257.	3.8	12
362	Smallâ€vessel disease in patients with Parkinson's disease: A clinicopathological study. Movement Disorders, 2012, 27, 1506-1512.	3.9	49
363	Multiple Biological Pathways Link Cognitive Lifestyle to Protection from Dementia. Biological Psychiatry, 2012, 71, 783-791.	1.3	83
364	Reduced T helper and B lymphocytes in Parkinson's disease. Journal of Neuroimmunology, 2012, 252, 95-99.	2.3	158
365	An emerging role for LRRK2 in the immune system. Biochemical Society Transactions, 2012, 40, 1134-1139.	3.4	36
366	Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields. , 2012, , 439-455.		23
367	Aspects of Innate Immunity and Parkinsonâ€™s Disease. Frontiers in Pharmacology, 2012, 3, 33.	3.5	17
368	A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Structure and Function, 2012, 217, 591-612.	2.3	136
369	Leucineâ€rich repeat kinase 2 and alternative splicing in Parkinson's disease. Movement Disorders, 2012, 27, 1004-1011.	3.9	13
370	Anterior cingulate integrity: Executive and neuropsychiatric features in Parkinson's disease. Movement Disorders, 2012, 27, 1262-1267.	3.9	45
371	Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?. Expert Review of Neurotherapeutics, 2012, 12, 673-686.	2.8	63
372	GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. Journal of Comparative Neurology, 2012, 520, 2591-2607.	1.6	76
373	Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T Î±-synuclein mutation. Translational Neurodegeneration, 2012, 1, 2.	8.0	24
374	Investigating visual misperceptions in Parkinson's disease: A novel behavioral paradigm. Movement Disorders, 2012, 27, 500-505.	3.9	41
375	The relationship between clinical and pathological variables in Richardsonâ€™s syndrome. Journal of Neurology, 2012, 259, 482-490.	3.6	19
376	Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1033-1037.	1.9	151
377	Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiology of Aging, 2011, 32, 257-271.	3.1	49
378	Interaction between Î±-Synuclein and Tau Genotypes and the Progression of Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 271-276.	2.8	14

#	ARTICLE	IF	CITATIONS
379	Genetic Polymorphisms in Sigma-1 Receptor and Apolipoprotein E Interact to Influence the Severity of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2011, 8, 765-770.	1.4	48
380	Overview and recent advances in neuropathology. Part 2: Neurodegeneration. <i>Pathology</i> , 2011, 43, 93-102.	0.6	7
381	An action spectrum for ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.5	90
382	Changes in the solubility and phosphorylation of α -synuclein over the course of Parkinson's disease. <i>Acta Neuropathologica</i> , 2011, 121, 695-704.	7.7	108
383	Neuropathology underlying clinical variability in patients with synucleinopathies. <i>Acta Neuropathologica</i> , 2011, 122, 187-204.	7.7	357
384	Striatal β -amyloid in dementia with Lewy bodies but not Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 713-719.	2.8	82
385	Pathological Staging of Frontotemporal Lobar Degeneration. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 379-383.	2.3	26
386	Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. <i>Movement Disorders</i> , 2011, 26, 256-263.	3.9	43
387	Clinical correlates of similar pathologies in parkinsonian syndromes. <i>Movement Disorders</i> , 2011, 26, 499-506.	3.9	17
388	Glia: Initiators and progressors of pathology in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 6-17.	3.9	383
389	Milestones in Parkinson's disease—Clinical and pathologic features. <i>Movement Disorders</i> , 2011, 26, 1015-1021.	3.9	150
390	Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks?. <i>Movement Disorders</i> , 2011, 26, 2154-2159.	3.9	164
391	Eating and hypothalamus changes in behavioral variant frontotemporal dementia. <i>Annals of Neurology</i> , 2011, 69, 312-319.	5.3	158
392	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. <i>Archives of Neurology</i> , 2011, 68, 488.	4.5	108
393	Clinical phenotypes in autopsy-confirmed Pick disease. <i>Neurology</i> , 2011, 76, 253-259.	1.1	42
394	Utility and Limitations of Addenbrooke's Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 349-357.	1.5	27
395	Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex. <i>PLoS ONE</i> , 2011, 6, e17299.	2.5	142
396	A23—Changes in key hypothalamic neuropeptide populations in Huntington's Disease revealed by neuropathological analyses. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, A7.3-A8.	1.9	0

#	ARTICLE	IF	CITATIONS
397	Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 981-984.	2.6	54
398	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. <i>Acta Neuropathologica</i> , 2010, 119, 1-4.	7.7	854
399	Focal demyelination in Alzheimer's disease and transgenic mouse models. <i>Acta Neuropathologica</i> , 2010, 119, 567-577.	7.7	155
400	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2010, 120, 33-41.	7.7	222
401	Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. <i>Acta Neuropathologica</i> , 2010, 120, 777-788.	7.7	93
402	Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. <i>BMC Neuroscience</i> , 2010, 11, 23.	1.9	25
403	Pigmentation in the human brain and risk of Parkinson's disease. <i>Annals of Neurology</i> , 2010, 67, 553-554.	5.3	4
404	Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration—motor neuron disease. <i>Annals of Neurology</i> , 2010, 68, 639-649.	5.3	168
405	Effect of age on proliferation-regulating factors in human adult neurogenic regions. <i>Journal of Neurochemistry</i> , 2010, 115, 956-964.	3.9	24
406	Immunohistochemical evidence for macroautophagy in neurones and endothelial cells in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 312-319.	3.2	70
407	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010, 42, 234-239.	21.4	479
408	Missing pieces in the Parkinson's disease puzzle. <i>Nature Medicine</i> , 2010, 16, 653-661.	30.7	621
409	Reply to: "Being too inclusive about synuclein inclusions". <i>Nature Medicine</i> , 2010, 16, 961-961.	30.7	0
410	The progression of pathology in Parkinson's disease. <i>Annals of the New York Academy of Sciences</i> , 2010, 1184, 188-195.	3.8	214
411	Increased ATP-Binding Cassette Transporter A1 Expression in Alzheimer's Disease Hippocampal Neurons. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 193-205.	2.6	39
412	Pathology of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 132-154.	0.1	6
413	The case of a 48 year-old woman with bizarre and complex delusions. <i>Nature Reviews Neurology</i> , 2010, 6, 175-179.	10.1	24
414	Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology. <i>Brain</i> , 2010, 133, e158-e158.	7.6	13

#	ARTICLE	IF	CITATIONS
415	Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 831-838.	2.4	32
416	Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?. <i>Progress in Neurobiology</i> , 2010, 92, 316-329.	5.7	106
417	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. <i>Lancet Neurology</i> , The, 2009, 8, 1150-1157.	10.2	734
418	Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?. <i>Movement Disorders</i> , 2009, 24, 833-838.	3.9	56
419	Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. <i>Movement Disorders</i> , 2009, 24, 290-292.	3.9	23
420	No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. <i>Movement Disorders</i> , 2009, 24, 1519-1523.	3.9	72
421	Unilateral rest tremor in vascular parkinsonism associated with a contralateral lesion of the locus coeruleus. <i>Movement Disorders</i> , 2009, 24, 1242-1244.	3.9	6
422	Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia. <i>Movement Disorders</i> , 2009, 24, 2128-2135.	3.9	13
423	Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. <i>Journal of Neural Transmission</i> , 2009, 116, 1243-1251.	2.8	35
424	Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2009, 117, 19-29.	7.7	26
425	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. <i>Acta Neuropathologica</i> , 2009, 117, 15-18.	7.7	377
426	Variations in the neuropathology of familial Alzheimer's disease. <i>Acta Neuropathologica</i> , 2009, 118, 37-52.	7.7	112
427	pH measurement as quality control on human <i>post mortem</i> brain tissue: a study of the BrainNet Europe consortium. <i>Neuropathology and Applied Neurobiology</i> , 2009, 35, 329-337.	3.2	93
428	Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2009, 161, 1357-1364.	1.5	75
429	Monocyte Chemoattractant Protein-1 Plays a Dominant Role in the Chronic Inflammation Observed in Alzheimer's Disease. <i>Brain Pathology</i> , 2009, 19, 392-398.	4.1	209
430	Tryptophan is a marker of human postmortem brain tissue quality. <i>Journal of Neurochemistry</i> , 2009, 110, 1400-1408.	3.9	13
431	Intralaminar nuclei of the thalamus in Lewy body diseases. <i>Brain Research Bulletin</i> , 2009, 78, 97-104.	3.0	50
432	Anti-melanin antibodies are increased in sera in Parkinson's disease. <i>Experimental Neurology</i> , 2009, 217, 297-301.	4.1	72

#	ARTICLE	IF	CITATIONS
433	White matter loss in healthy ageing: A postmortem analysis. <i>Neurobiology of Aging</i> , 2009, 30, 1288-1295.	3.1	62
434	The neural basis of semantic memory: Evidence from semantic dementia. <i>Neurobiology of Aging</i> , 2009, 30, 2043-2052.	3.1	47
435	O.064 Thalamic changes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S17.	2.2	0
436	P3.061 Differential distribution of tyrosine hydroxylase isoforms in the human brain. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S164.	2.2	0
437	Thalamic changes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S152-S155.	2.2	132
438	Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009, 21, 688-695.	1.0	16
439	Degeneration in Different Parkinsonian Syndromes Relates to Astrocyte Type and Astrocyte Protein Expression. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1073-1083.	1.7	173
440	Variable phenotype of Alzheimer's disease with spastic paraparesis. <i>Journal of Neurochemistry</i> , 2008, 104, 573-583.	3.9	54
441	The comparative biology of neuromelanin and lipofuscin in the human brain. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 1669-1682.	5.4	166
442	The progression of pathology in longitudinally followed patients with Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 409-415.	7.7	337
443	Clarifying the pathological progression of Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 377-378.	7.7	10
444	LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. <i>Acta Neuropathologica</i> , 2008, 116, 639-646.	7.7	43
445	Excessive dopamine neuron loss in progressive supranuclear palsy. <i>Movement Disorders</i> , 2008, 23, 607-610.	3.9	27
446	The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. <i>Movement Disorders</i> , 2008, 23, 837-844.	3.9	1,779
447	Haplotype analysis of the IGF2BP3 gene cluster in Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 495-499.	1.7	17
448	Pedigree with frontotemporal lobar degeneration - motor neuron disease and Tau DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. <i>BMC Neurology</i> , 2008, 8, 32.	1.8	71
449	Human-based studies on α -synuclein deposition and relationship to Parkinson's disease symptoms. <i>Experimental Neurology</i> , 2008, 209, 12-21.	4.1	39
450	Neuropathologic correlates of white matter hyperintensities. <i>Neurology</i> , 2008, 71, 804-811.	1.1	291

#	ARTICLE	IF	CITATIONS
451	Clinical Significance of Lobar Atrophy in Frontotemporal Dementia: Application of an MRI Visual Rating Scale. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 334-342.	1.5	150
452	Genetics of Parkinson's Disease. , 2007, , 663-697.		5
453	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 251-257.	1.7	104
454	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 329-336.	1.7	41
455	VISAâ€”A pass to innate immunity. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 287-291.	2.8	18
456	Tau isoform expression in frontotemporal dementia without tau deposition. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 1182-1185.	1.5	7
457	A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. <i>Neuroscience Letters</i> , 2007, 414, 170-173.	2.1	9
458	Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing. <i>NeuroImage</i> , 2007, 34, 1054-1059.	4.2	66
459	p25± Relocalizes in Oligodendroglia from Myelin to Cytoplasmic Inclusions in Multiple System Atrophy. <i>American Journal of Pathology</i> , 2007, 171, 1291-1303.	3.8	169
460	Clinicopathological aspects of motor parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S208-S210.	2.2	7
461	ORGANIZATION: PYRAMIDAL AND EXTRAPYRAMIDAL SYSTEM. , 2007, , 396-401.		0
462	Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's Disease. <i>Movement Disorders</i> , 2007, 22, 982-989.	3.9	34
463	Relationship between neuronal loss and ?inflammatory plaques? in early onset Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 328-333.	3.2	11
464	Parkin Co-regulated Gene (PACRG) is regulated by the ubiquitinâ€”proteasomal system and is present in the pathological features of parkinsonian diseases. <i>Neurobiology of Disease</i> , 2007, 27, 238-247.	4.4	32
465	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. <i>Acta Neuropathologica</i> , 2007, 114, 5-22.	7.7	978
466	Lipid content determines aggregation of neuromelanin granules in vitro. , 2007, , 35-38.		5
467	Physiologic and Neurotoxic Properties of AÎ² Peptides. , 2007, , 179-197.		0
468	New face of neuromelanin. , 2006, , 119-123.		26

#	ARTICLE	IF	CITATIONS
469	Antigen-Epitope Retrieval To Facilitate Proteomic Analysis of Formalin-Fixed Archival Brain Tissue. <i>Analytical Chemistry</i> , 2006, 78, 7216-7221.	6.5	26
470	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 309-313.	2.2	3
471	Evidence for specific phases in the development of human neuromelanin. <i>Neurobiology of Aging</i> , 2006, 27, 506-512.	3.1	57
472	Differences in regional brain atrophy in genetic forms of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 387-393.	3.1	31
473	Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1554-1563.	3.1	146
474	Neuropathology in the S305S tau gene mutation. <i>Brain</i> , 2006, 129, E40-E40.	7.6	17
475	Î²-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. <i>Proteomics</i> , 2006, 6, 6566-6577.	2.2	62
476	Cognitive, Extrapyramidal, and Magnetic Resonance Imaging Predictors of Functional Impairment in Nondemented Older Community Dwellers: The Sydney Older Person Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 3-10.	2.6	31
477	Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2006, 154, 72-78.	1.5	56
478	Inhibition of nitric oxide and reactive oxygen species production improves the ability of a sunscreen to protect from sunburn, immunosuppression and photocarcinogenesis. <i>British Journal of Dermatology</i> , 2006, 155, 408-415.	1.5	38
479	Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neurone disease identifies a group with mainly early pathology. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 83-91.	3.2	27
480	Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 374-387.	3.2	34
481	Evidence for specific phases in the development of human neuromelanin. <i>Journal of Neural Transmission</i> , 2006, 113, 721-728.	2.8	35
482	Investigation of the lipid component of neuromelanin. <i>Journal of Neural Transmission</i> , 2006, 113, 735-739.	2.8	10
483	P25Î± immunoreactive but Î±-synuclein immunonegative neuronal inclusions in multiple system atrophy. <i>Acta Neuropathologica</i> , 2006, 111, 193-195.	7.7	25
484	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. <i>Acta Neuropathologica</i> , 2006, 111, 329-340.	7.7	91
485	A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 171-179.	2.7	30
486	Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 632-638.	3.9	52

#	ARTICLE	IF	CITATIONS
487	Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain, 2006, 129, 3124-3126.	7.6	91
488	Progression in Frontotemporal Dementia. Archives of Neurology, 2006, 63, 1627.	4.5	189
489	Preserved Cognition and Functional Independence after a Large Right Posterior Cerebral Artery Infarct: Longitudinal Clinical and Neuropathological Findings. Neurocase, 2006, 12, 81-90.	0.6	4
490	Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. , 2006, , 99-103.		77
491	Diagnosis and management of dementia with Lewy bodies. Neurology, 2005, 65, 1863-1872.	1.1	4,604
492	Dolichol is the major lipid component of human substantia nigra neuromelanin. Journal of Neurochemistry, 2005, 92, 990-995.	3.9	61
493	Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. Journal of Neurochemistry, 2005, 95, 599-608.	3.9	28
494	Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease. Neuropathology and Applied Neurobiology, 2005, 31, 503-511.	3.2	19
495	Clarifying Lewy-body parkinsonism with visual hallucinations. Lancet Neurology, The, 2005, 4, 588-589.	10.2	3
496	Pick bodies in a family with presenilin-1 Alzheimer's disease. Annals of Neurology, 2005, 57, 139-143.	5.3	60
497	GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Annals of Neurology, 2005, 58, 829-839.	5.3	191
498	Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. Movement Disorders, 2005, 20, 34-39.	3.9	22
499	Pallidal stimulation reduces treatment-induced dyskinesias in 'minimal' change multiple system atrophy. Movement Disorders, 2005, 20, 1042-1047.	3.9	25
500	What is the dominant α^2 species in human brain tissue? A review. Neurotoxicity Research, 2005, 7, 29-41.	2.7	41
501	Insoluble β -synuclein in alzheimer's disease without lewy body formation. Neurotoxicity Research, 2005, 7, 69-76.	2.7	10
502	The emergence of proto-objects in complex visual hallucinations. Behavioral and Brain Sciences, 2005, 28, 767-768.	0.7	2
503	A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain, 2005, 128, 2272-2280.	7.6	100
504	The pathological basis of semantic dementia. Brain, 2005, 128, 1984-1995.	7.6	313

#	ARTICLE	IF	CITATIONS
505	A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain, 2005, 128, 2665-2674.	7.6	307
506	Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain, 2005, 128, 597-605.	7.6	167
507	Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain, 2005, 128, 1259-1266.	7.6	133
508	Î±-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain, 2005, 128, 2654-2664.	7.6	187
509	Phosphorylation of Apolipoprotein-E at an Atypical Protein Kinase CK2 PSD/E Site in Vitro. Biochemistry, 2005, 44, 7346-7353.	2.5	28
510	Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease. Progress in Neurobiology, 2005, 75, 109-124.	5.7	313
511	Localization of immunoreactivity for Deleted in Colorectal Cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience, 2005, 131, 671-681.	2.3	69
512	Distribution of brain atrophy in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 2005, 232, 83-90.	0.6	78
513	Variable Phenotype of Alzheimer's Disease with Spastic Paraparesis. Research and Perspectives in Alzheimer's Disease, 2005, , 73-92.	0.1	1
514	Thalamic and Cortical Changes in Parkinsonian Disorders. , 2005, , 415-424.		0
515	Organization of Human Brain Stem Nuclei. , 2004, , 267-320.		21
516	Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain, 2004, 127, 2214-2220.	7.6	93
517	The Serotonin and Tachykinin Systems. , 2004, , 1205-1256.		10
518	Similar early clinical presentations in familial and non-familial frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1743-1745.	1.9	25
519	Clinicopathological Staging of Frontotemporal Dementia Severity: Correlation with Regional Atrophy. Dementia and Geriatric Cognitive Disorders, 2004, 17, 311-315.	1.5	83
520	Substantia Nigra and Locus Coeruleus. , 2004, , 449-463.		23
521	Are Parkinson's Disease with dementia and Dementia with lewy Bodies the Same Entity?. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 137-145.	2.3	180
522	Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma. British Journal of Dermatology, 2004, 151, 42-49.	1.5	18

#	ARTICLE	IF	CITATIONS
523	Dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2004, 3, 19-28.	10.2	645
524	Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. <i>Acta Neuropathologica</i> , 2004, 108, 515-523.	7.7	105
525	Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. <i>Journal of Neurology</i> , 2004, 251, 1098-104.	3.6	43
526	Identification of families with cortical Lewy body disease. <i>American Journal of Medical Genetics Part A</i> , 2004, 128B, 118-122.	2.4	13
527	Clinicopathological correlates in frontotemporal dementia. <i>Annals of Neurology</i> , 2004, 56, 399-406.	5.3	549
528	Partial lesion of thalamic ventral intermediate nucleus after chronic high-frequency stimulation. <i>Movement Disorders</i> , 2004, 19, 709-711.	3.9	11
529	Genetic contributions to Parkinson's disease. <i>Brain Research Reviews</i> , 2004, 46, 44-70.	9.0	83
530	A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 191-202.	2.2	50
531	Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. <i>Neurobiology of Disease</i> , 2004, 15, 115-119.	4.4	33
532	Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 361, 9-12.	2.1	53
533	Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. <i>Neurology</i> , 2004, 63, 1613-1617.	1.1	35
534	The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. <i>Experimental Neurology</i> , 2003, 184, 530-535.	4.1	31
535	Identifying severely atrophic cortical subregions in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 797-806.	3.1	61
536	Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. <i>Behavioural Brain Research</i> , 2003, 139, 105-113.	2.2	59
537	The left human speech-processing cortex is thinner but longer than the right. <i>Laterality</i> , 2003, 8, 247-260.	1.0	58
538	Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test. <i>Archives of Neurology</i> , 2003, 60, 545.	4.5	172
539	Presenilin-1 Mutation L271V Results in Altered Exon 8 Splicing and Alzheimer's Disease with Non-cored Plaques and No Neuritic Dystrophy. <i>Journal of Biological Chemistry</i> , 2003, 278, 6748-6754.	3.4	54
540	Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. <i>Brain</i> , 2003, 126, 814-826.	7.6	114

#	ARTICLE	IF	CITATIONS
541	Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 956-958.	1.9	24
542	Genetically confirmed clinical Huntington's disease with no observable cell loss. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 968-970.	1.9	31
543	Survival in frontotemporal dementia. Neurology, 2003, 61, 349-354.	1.1	355
544	Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain, 2003, 126, 827-840.	7.6	78
545	Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology, 2003, 60, 1005-1011.	1.1	247
546	A 6-Year Study of Cognition and Spatial Function in the Demented and Non-Demented Elderly: The Sydney Older Persons Study. Dementia and Geriatric Cognitive Disorders, 2003, 16, 181-186.	1.5	14
547	Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 747-751.	1.9	116
548	Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 2002, 125, 391-403.	7.6	587
549	Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain, 2002, 125, 2431-2445.	7.6	383
550	Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. NeuroReport, 2002, 13, 601-604.	1.2	31
551	Neurofilament-Immunoreactive Neurons in Alzheimer's Disease and Dementia with Lewy Bodies. Neurobiology of Disease, 2002, 9, 249-257.	4.4	37
552	Pyramidal Cell Loss in Motor Cortices in Huntington's Disease. Neurobiology of Disease, 2002, 10, 378-386.	4.4	101
553	An inflammatory review of Parkinson's disease. Progress in Neurobiology, 2002, 68, 325-340.	5.7	297
554	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain, 2002, 125, 789-800.	7.6	126
555	Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Movement Disorders, 2002, 17, 1166-1173.	3.9	111
556	Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. Movement Disorders, 2002, 17, 133-137.	3.9	91
557	Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: Volume and neuronal number for the output, internal relay, and striatal modulating nuclei. Journal of Comparative Neurology, 2002, 445, 238-255.	1.6	223
558	Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathologica, 2002, 103, 370-376.	7.7	159

#	ARTICLE	IF	CITATIONS
559	Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. <i>Acta Neuropathologica</i> , 2002, 104, 72-78.	7.7	54
560	Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. <i>British Journal of Dermatology</i> , 2002, 146, 810-815.	1.5	107
561	Selective hippocampal neuron loss in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2002, 51, 125-128.	5.3	53
562	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. <i>Brain</i> , 2002, 125, 789-800.	7.6	24
563	Which Basal Ganglia Surgical Targets Ameliorate Parkinsonian Symptoms?. <i>Advances in Behavioral Biology</i> , 2002, , 533-542.	0.2	0
564	Neurofilament-Immunoreactive Neurons Are Not Selectively Vulnerable in Alzheimer's Disease. <i>Neurobiology of Disease</i> , 2001, 8, 136-146.	4.4	8
565	Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2001, 101, 616-624.	7.7	48
566	Cortical Lewy body pathology in the diagnosis of dementia. <i>Acta Neuropathologica</i> , 2001, 102, 355-363.	7.7	262
567	Parkinson's disease with late Pick's dementia. <i>Movement Disorders</i> , 2001, 16, 311-319.	3.9	12
568	Corticobasal syndrome with tau pathology. <i>Movement Disorders</i> , 2001, 16, 656-667.	3.9	61
569	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α -synuclein mutation. <i>Annals of Neurology</i> , 2001, 49, 313-319.	5.3	364
570	Severe Anterograde Amnesia with Extensive Hippocampal Degeneration in a Case of Rapidly Progressive Frontotemporal Dementia.. <i>Neurocase</i> , 2001, 7, 57-64.	0.6	24
571	Alzheimer's disease: Its diagnosis and pathogenesis. <i>International Review of Neurobiology</i> , 2001, 48, 167-217.	2.0	17
572	Lesion of thalamic centromedian α parafascicular complex after chronic deep brain stimulation. <i>Neurology</i> , 2001, 56, 1576-1579.	1.1	51
573	Cortical degeneration associated with phonologic and semantic language impairments in AD. <i>Neurology</i> , 2001, 56, 944-950.	1.1	39
574	Transforming growth factor- β 2 produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. <i>International Immunology</i> , 2001, 13, 1147-1154.	4.0	59
575	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α -synuclein mutation. <i>Annals of Neurology</i> , 2001, 49, 313-319.	5.3	6
576	Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr α -synuclein mutation. <i>Annals of Neurology</i> , 2001, 49, 313-9.	5.3	98

#	ARTICLE	IF	CITATIONS
577	A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. Brain, 2000, 123, 724-732.	7.6	41
578	Degeneration of the central median-parafascicular complex in Parkinson's disease. Annals of Neurology, 2000, 47, 345-352.	5.3	165
579	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Annals of Neurology, 2000, 47, 718-728.	5.3	116
580	Topical Retinoic Acid Enhances, and a Dark Tan Protects, from Subdermal Solar-Simulated Photocarcinogenesis. Journal of Investigative Dermatology, 2000, 114, 923-927.	0.7	36
581	Cytokine profiles in spontaneously regressing basal cell carcinomas. British Journal of Dermatology, 2000, 143, 91-98.	1.5	84
582	Alzheimer's Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 1-8.	1.9	174
583	Practical measures to simplify the Braak tangle staging method for routine pathological screening. Acta Neuropathologica, 2000, 99, 199-208.	7.7	42
584	Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene. Brain, 2000, 123, 880-893.	7.6	277
585	Cortical Inflammation in Alzheimer Disease but Not Dementia With Lewy Bodies. Archives of Neurology, 2000, 57, 817.	4.5	67
586	Anti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses. Archives of Neurology, 2000, 57, 1586-91.	4.5	146
587	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. Archives of Neurology, 2000, 57, 831.	4.5	69
588	Idiopathic generalized epilepsy. Neurology, 2000, 55, 1101-1106.	1.1	57
589	Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain, 2000, 123, 1410-1421.	7.6	219
590	Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia. Life Sciences, 2000, 66, 1345-1350.	4.3	10
591	Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. Brain, 2000, 123, 141-154.	7.6	351
592	Degeneration of the central median-parafascicular complex in Parkinson's disease. Annals of Neurology, 2000, 47, 345-352.	5.3	6
593	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. , 2000, 47, 718.		1
594	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Annals of Neurology, 2000, 47, 718-728.	5.3	4

#	ARTICLE	IF	CITATIONS
595	Degeneration of the central median-parafascicular complex in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 345-52.	5.3	73
596	Specific temporoparietal gyral atrophy reflects the pattern of language dissolution in Alzheimer's disease. <i>Brain</i> , 1999, 122, 675-686.	7.6	87
597	Effect of inhibitors of oxygen radical and nitric oxide formation on UV radiation-induced erythema, immunosuppression and carcinogenesis. <i>Redox Report</i> , 1999, 4, 316-319.	4.5	18
598	The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. <i>Movement Disorders</i> , 1999, 14, 626-633.	3.9	35
599	Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 149-154.	1.5	3
600	Neuronal loss in functional zones of the cerebellum of chronic alcoholics with and without Wernicke's encephalopathy. <i>Neuroscience</i> , 1999, 91, 429-438.	2.3	167
601	Brain shrinkage in alcoholics: a decade on and what have we learned?. <i>Progress in Neurobiology</i> , 1999, 58, 381-387.	5.7	172
602	The Internal Globus Pallidus Is Affected in Progressive Supranuclear Palsy and Parkinson's Disease. <i>Experimental Neurology</i> , 1999, 158, 135-142.	4.1	38
603	Clinical and Neuropathological Abnormalities in Baboons Treated with HTP, the Tetrahydropyridine Analog of Haloperidol. <i>Experimental Neurology</i> , 1999, 158, 155-163.	4.1	18
604	Sunscreens and vitamin E provide some protection to the skin immune system from solar-simulated UV radiation. <i>Australasian Journal of Dermatology</i> , 1998, 39, 71-75.	0.7	4
605	Simplified neuropathological diagnosis of dementia with Lewy bodies. <i>Neuropathology and Applied Neurobiology</i> , 1998, 24, 195-201.	3.2	38
606	Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. <i>Neurobiology of Aging</i> , 1998, 19, 297-306.	3.1	53
607	The midbrain dopaminergic cell groups in the baboon <i>papio ursinus</i> . <i>Brain Research Bulletin</i> , 1998, 47, 611-623.	3.0	16
608	Regional Specificity of Brain Atrophy in Huntington's Disease. <i>Experimental Neurology</i> , 1998, 154, 663-672.	4.1	224
609	Variation in hippocampal neuron number with age and brain volume. <i>Cerebral Cortex</i> , 1998, 8, 710-718.	2.9	96
610	Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease. <i>NeuroReport</i> , 1998, 9, 3335-3339.	1.2	68
611	The nucleus basalis (Ch4) in the alcoholic Wernicke-Korsakoff syndrome: reduced cell number in both amnesic and non-amnesic patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 63, 315-320.	1.9	41
612	Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 51-60.	1.9	373

#	ARTICLE	IF	CITATIONS
613	Utilising Molecular Biological and Histopathological Techniques to Study the Dopaminergic System in Patients with Melancholia. Australian and New Zealand Journal of Psychiatry, 1997, 31, 27-35.	2.3	7
614	Language-Associated Cortical Regions Are Proportionally Larger in the Female Brain. Archives of Neurology, 1997, 54, 171-176.	4.5	224
615	The Subthalamic Nucleus in Parkinson's Disease and Progressive Supranuclear Palsy. Journal of Neuropathology and Experimental Neurology, 1997, 56, 132-142.	1.7	60
616	Progressive Supranuclear Palsy Affects both the Substantia Nigra Pars Compacta and Reticulata. Experimental Neurology, 1997, 144, 183-192.	4.1	58
617	Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease. Experimental Neurology, 1997, 144, 202-213.	4.1	118
618	Further evidence for an association between a mutation in the APP gene and Lewy body formation. Neuroscience Letters, 1997, 227, 49-52.	2.1	27
619	Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. Neuroscience, 1997, 78, 641-652.	2.3	60
620	The cerebral cortex is damaged in chronic alcoholics. Neuroscience, 1997, 79, 983-998.	2.3	474
621	Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. Neuropathology and Applied Neurobiology, 1997, 23, 492-495.	3.2	50
622	Prediction of minimal erythema dose with a reflectance melanin meter. British Journal of Dermatology, 1997, 136, 714-718.	1.5	5
623	Chronic alcohol consumption does not cause hippocampal neuron loss in humans. , 1997, 7, 78-87.		148
624	Topography of brain atrophy during normal aging and Alzheimer's disease. Neurobiology of Aging, 1996, 17, 513-521.	3.1	170
625	Glial fibrillary acidic protein (GFAP) immunohistochemistry in human cortex: a quantitative study using different antisera. Neuroscience Letters, 1996, 209, 29-32.	2.1	48
626	Loss of vasopressin-immunoreactive neurons in alcoholics is dose-related and time-dependent. Neuroscience, 1996, 72, 699-708.	2.3	137
627	Substantia Nigra Pars Reticulata Neurons in Parkinson's Disease. Experimental Neurology, 1996, 5, 49-55.	1.7	56
628	Improved Selectivity and Sensitivity in the Visualization of Neurofibrillary Tangles, Plaques and Neuropil Threads. Experimental Neurology, 1996, 5, 177-187.	1.7	19
629	Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. Journal of Clinical Neuroscience, 1996, 3, 52-60.	1.5	93
630	Quantification of cortical atrophy in a case of progressive fluent aphasia. Brain, 1996, 119, 181-190.	7.6	95

#	ARTICLE	IF	CITATIONS
631	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. Journal of Histotechnology, 1996, 19, 33-38.	0.5	6
632	Regional Brain Atrophy in Idiopathic Parkinson's Disease and Diffuse Lewy Body Disease. Dementia and Geriatric Cognitive Disorders, 1996, 7, 304-313.	1.5	30
633	Chronic alcoholism in the absence of Wernicke-Korsakoff syndrome and cirrhosis does not result in the loss of serotonergic neurons from the median raphe nucleus. Metabolic Brain Disease, 1996, 11, 217-227.	2.9	12
634	Anatomical and immunohistochemical identification of catecholaminergic neurones in brain slice preparations used in electrophysiology. Journal of Neuroscience Methods, 1996, 64, 83-93.	2.5	11
635	Diagnostic evaluation of the substantia nigra. Neuropathology and Applied Neurobiology, 1996, 22, 228-232.	3.2	3
636	Chronic Alcoholics without Wernicke-Korsakoff Syndrome or Cirrhosis Do Not Lose Serotonergic Neurons in the Dorsal Raphe Nucleus. Alcoholism: Clinical and Experimental Research, 1996, 20, 61-66.	2.4	30
637	NORADRENERGIC LOCUS COERULEUS NEURONS. Alcoholism: Clinical and Experimental Research, 1996, 20, 191-192.	2.4	6
638	Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. Journal of Comparative Neurology, 1996, 364, 121-150.	1.6	164
639	Reproducible sampling regimen for specific cortical regions: application to speech-associated areas. Journal of Neuroscience Methods, 1996, 67, 43-51.	2.5	22
640	Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 531-538.	1.9	52
641	Pattern of Midbrain Pathology in Different Parkinsonian Syndromes. Advances in Behavioral Biology, 1996, , 441-444.	0.2	2
642	Diagnostic evaluation of the substantia nigra. Neuropathology and Applied Neurobiology, 1996, 22, 228-232.	3.2	4
643	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. Journal of Histotechnology, 1996, 19, 33-38.	0.5	4
644	Brain stem nuclei in sudden infant death syndrome (SIDS): volumes, neuronal numbers and positions. Neuropathology and Applied Neurobiology, 1995, 21, 262-268.	3.2	12
645	Neurofibrillary tangles in chronic alcoholics. Neuropathology and Applied Neurobiology, 1995, 21, 312-318.	3.2	41
646	Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4 ⁺ T cells. World Journal of Surgery, 1995, 19, 352-358.	1.6	134
647	Ubiquitin-positive achromatic neurons in corticobasal degeneration. Acta Neuropathologica, 1995, 90, 68-75.	7.7	39
648	Comparison of the Number of Vasopressin-Producing Hypothalamic Neurons in Rats and Humans. Journal of Neuroendocrinology, 1995, 7, 629-636.	2.6	14

#	ARTICLE	IF	CITATIONS
649	Serotonin and alcohol-related brain damage. Metabolic Brain Disease, 1995, 10, 25-30.	2.9	28
650	Mechanisms of cell death in cholinergic basal forebrain neurons in chronic alcoholics. Metabolic Brain Disease, 1995, 10, 81-91.	2.9	34
651	Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans. Neuroscience, 1995, 65, 87-91.	2.3	53
652	Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. Neuroscience, 1995, 68, 539-551.	2.3	54
653	Ascending Noradrenergic and Serotonergic Systems in the Human Brainstem. Advances in Behavioral Biology, 1995, , 155-171.	0.2	2
654	Cytoarchitecture and Chemistry of Midbrain Dopaminergic Cell Groups. Advances in Behavioral Biology, 1995, , 115-127.	0.2	1
655	Ubiquitin-positive achromatic neurons in corticobasal degeneration. Acta Neuropathologica, 1995, 90, 68-75.	7.7	8
656	Neurotransmitter Changes in Alzheimer's Disease. Advances in Behavioral Biology, 1995, , 199-219.	0.2	5
657	Cytoarchitecture and Chemistry of the Human Ascending Cholinergic System. Advances in Behavioral Biology, 1995, , 129-153.	0.2	0
658	Practical considerations for the use of the optical disector in estimating neuronal number. Journal of Neuroscience Methods, 1994, 51, 83-89.	2.5	82
659	Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathologica, 1994, 87, 174-186.	7.7	30
660	Regression in basal cell carcinoma: an immunohistochemical analysis. British Journal of Dermatology, 1994, 130, 1-8.	1.5	135
661	Effect of Chronic Alcohol Consumption on the Human Locus Coeruleus. Alcoholism: Clinical and Experimental Research, 1994, 18, 1491-1496.	2.4	26
662	Neuropathological correlates of memory dysfunction in the Wernicke-Korsakoff syndrome. Alcohol and Alcoholism Supplement, 1994, 2, 245-51.	0.0	12
663	Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathologica, 1994, 87, 174-186.	7.7	4
664	Quantitation and three-dimensional reconstruction of Ch4 nucleus in the human basal forebrain. Synapse, 1993, 15, 1-16.	1.2	45
665	Carcinogen-Treated Skin Allografts Rejected by T Lymphocytes Specific for Class I but Not Class II MHC Antigens. Cellular Immunology, 1993, 151, 291-299.	3.0	0
666	Thalamic vacuolation in acute Wernicke's encephalopathy. Metabolic Brain Disease, 1993, 8, 107-113.	2.9	9

#	ARTICLE	IF	CITATIONS
667	Parvalbumin as an anatomical marker for discrete subregions of the ambiguous complex in the rat. <i>Neuroscience Letters</i> , 1993, 160, 101-105.	2.1	77
668	Brainstem Serotonergic Neurons in Chronic Alcoholics With and Without the Memory Impairment of Korsakoff's Psychosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 567-579.	1.7	68
669	Protein kinase C transduces the signal for Langerhans' cell migration from the epidermis. <i>Immunology</i> , 1993, 79, 621-6.	4.4	27
670	Topical retinoic acid inhibits changes in Langerhans cell density during carcinogenesis. <i>In Vivo</i> , 1993, 7, 271-6.	1.3	3
671	Preliminary Evidence Suggesting Delayed Development in the Hypoglossal and Vagal Nuclei of SIDS Infants: A Necropsy Study. <i>Journal of Child Neurology</i> , 1992, 7, 44-49.	1.4	29
672	A Comparative Study of Avidin-Biotin-Peroxidase Complexes for the Immunohistochemical Detection of Antigens in Neural Tissue. <i>Biotechnic and Histochemistry</i> , 1992, 67, 367-371.	1.3	17
673	Application of antiphenylalanine hydroxylase antibodies to the study of the serotonergic system in the human brain. <i>Journal of Chemical Neuroanatomy</i> , 1992, 5, 311-313.	2.1	19
674	Rostrocaudal differences in morphology and neurotransmitter content of cells in the subretrofacial vasomotor nucleus. <i>Journal of the Autonomic Nervous System</i> , 1992, 38, 117-137.	1.9	35
675	The locus coeruleus and memory: a study of chronic alcoholics with and without the memory impairment of Korsakoff's psychosis. <i>Brain Research</i> , 1992, 598, 33-37.	2.2	39
676	Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. <i>Acta Neuropathologica</i> , 1992, 84, 638-50.	7.7	95
677	Regulation of the Skin Immune System by Retinoids During Carcinogenesis. <i>Journal of Investigative Dermatology</i> , 1992, 99, S83-S86.	0.7	20
678	The dorsal, posterodorsal, and ventral tegmental nuclei: A cyto- and chemoarchitectonic study in the human. <i>Journal of Comparative Neurology</i> , 1992, 318, 117-137.	1.6	21
679	Control of Langerhans' cell density by a skin tumour-derived cytokine. <i>Immunology</i> , 1992, 77, 13-8.	4.4	31
680	Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. <i>Neuroscience</i> , 1991, 42, 757-775.	2.3	202
681	A comparative analysis of neurons containing catecholamine-synthesizing enzymes and neuropeptide Y in the ventrolateral medulla of rats, guinea-pigs and cats. <i>Neuroscience</i> , 1991, 43, 531-550.	2.3	47
682	Four groups of tyrosine hydroxylase-immunoreactive neurons in the ventrolateral medulla of rats, guinea-pigs and cats identified on the basis of chemistry, topography and morphology. <i>Neuroscience</i> , 1991, 43, 551-568.	2.3	20
683	Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. <i>Synapse</i> , 1991, 7, 301-320.	1.2	84
684	SUBSTANCE P-CONTAINING NEURONS IN THE MESOPONTINE TEGMENTUM ARE SEVERELY AFFECTED IN PARKINSON'S DISEASE. <i>Brain</i> , 1991, 114, 2253-2267.	7.6	89

#	ARTICLE	IF	CITATIONS
685	Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Annals of Neurology, 1990, 27, 373-385.	5.3	346
686	Cytoarchitecture of the human dorsal raphe nucleus. Journal of Comparative Neurology, 1990, 301, 147-161.	1.6	145
687	Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain. Neuroscience, 1990, 39, 81-96.	2.3	41
688	Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Research, 1990, 510, 104-107.	2.2	320
689	Human Homologs to Brainstem Nuclei Identified in Other Animals as Revealed by Acetylcholinesterase Activity. , 1990, , 149-202.		54
690	Catecholaminergic Neurons. , 1990, , 1023-1049.		29
691	Serotonin-like immunoreactive cells and fibres in the rat ventromedial mesencephalic tegmentum. Brain Research Bulletin, 1989, 22, 725-735.	3.0	41
692	Distribution of monoamine-synthesizing neurons in the human medulla oblongata. Journal of Comparative Neurology, 1988, 273, 301-317.	1.6	121
693	Distribution of substance P-like immunoreactive neurons in the human medulla oblongata: Co-localization with monoamine-synthesizing neurons. Synapse, 1988, 2, 353-370.	1.2	60
694	Tyrosine hydroxylase-containing neurons in the supraoptic and paraventricular nuclei of the adult human. Brain Research, 1988, 461, 75-86.	2.2	42
695	Substance P-like immunoreactive fibres in the ventromedial mesencephalic tegmentum of rat. Brain Research Bulletin, 1988, 21, 659-670.	3.0	10
696	The distribution of neuropeptide Y-like immunoreactive neurons in the human medulla oblongata. Neuroscience, 1988, 26, 179-191.	2.3	52
697	Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Research Reviews, 1987, 12, 117-165.	9.0	873
698	Comparative anatomy of the ventromedial mesencephalic tegmentum in the rat, cat, monkey and human. Journal of Comparative Neurology, 1986, 252, 423-445.	1.6	133
699	Electron microscopic analysis of the mesencephalic ventromedial tegmentum in the cat. Journal of Comparative Neurology, 1984, 230, 393-412.	1.6	11
700	An adaptive measure of visuospatial impairment in Dementia with Lewy Bodies. Movement Disorders Clinical Practice, 0, , .	1.5	2